Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 55.38

Qlife Holding AB (publ) Price to Sales Ratio (P/S) is 55.38 on January 14, 2025, a 85,203.80% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Qlife Holding AB (publ) 52-week high Price to Sales Ratio (P/S) is 93.85 on September 05, 2024, which is 69.46% above the current Price to Sales Ratio (P/S).
Qlife Holding AB (publ) 52-week low Price to Sales Ratio (P/S) is 0.02 on June 28, 2024, which is -99.97% below the current Price to Sales Ratio (P/S).
Qlife Holding AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 36.73.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years